|Articles|March 1, 2002

March 2002
Volume 8
Issue 3

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

Author(s)Susan G. Blitz, MD, MPH, Peter Cram, MD, Michael E. Chernew, PhD

Download PDF: Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

Articles in this issue

over 24 years ago

Article

Application of Cost-Effectiveness Analysis to Multiple Products: A Practical Guide

over 24 years ago

Article

over 24 years ago

Article

over 24 years ago

Article

Development and Maintenance of a Community-Based Hepatitis C Registry

over 24 years ago

Article

Value for Money in Health and Medical Care Services

over 24 years ago

Article

Use of Alternative Pharmacotherapy in Management of Cardiovascular Diseases

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

Biologics Appear Renal-Safe in Psoriasis, IL-17 Agents Show Kidney Promise

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

Biologics Appear Renal-Safe in Psoriasis, IL-17 Agents Show Kidney Promise

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease